http://comum.rcaap.pt/handle/123456789/1890 2013-06-20T08:09:04Z 2013-06-20T08:09:04Z Ribas, S Soares, V Koch, P http://comum.rcaap.pt/handle/123456789/3655 2013-06-05T01:25:07Z 2008-01-01T00:00:00Z

Title: Grupo de Biópsia Aspirativa com Agulha Fina: análise dos primeiros 500 casos Authors: Ribas, S; Soares, V; Koch, P Abstract: O Grupo de Biópsia Aspirativa com Agulha Fina está integrado na Unidade de Cabeça e Pescoço que pertence ao Departamento de Cirurgia do Hospital de S. Marcos. Este grupo foi constituído e iniciou a sua actividade em 2005 e é responsável pela realização de biópsias aspirativas de agulha fina, directas e ecoguiadas, de nódulos localizados na cabeça e pescoço. Este trabalho pretende analisar os primeiros 500 casos de biópsias aspirativas com agulha fina da glândula tiróide. The Group of Fine-needle Aspiration Biopsy is a part of the Unit for Head and Neck which belongs to the Department of Surgery of the Hospital of S. Marcos. This group was formed and started his activity in 2005 and is responsible for carrying out fine needle aspiration biopsies, direct and ultrasound-guided, of nodules found in the head and neck. This paper aims to examine the first 500 cases of fine-needle aspiration biopsies of the thyroid gland.

2008-01-01T00:00:00Z Costa, BM Viana-Pereira, M Fernandes, R Costa, S Linhares, P Vaz, R Pinheiro, C Lima, J Soares, P Silva, A Pardal, F Amorim, J Nabiço, R Almeida, R Alegria, C Pires, MM Pinheiro, C Carvalho, E Oliveira, P Lopes, JM Reis, RM http://comum.rcaap.pt/handle/123456789/3590 2013-06-05T01:23:13Z 2011-01-01T00:00:00Z

Title: Impact of EGFR genetic variants on glioma risk and patient outcome Authors: Costa, BM; Viana-Pereira, M; Fernandes, R; Costa, S; Linhares, P; Vaz, R; Pinheiro, C; Lima, J; Soares, P; Silva, A; Pardal, F; Amorim, J; Nabiço, R; Almeida, R; Alegria, C; Pires, MM; Pinheiro, C; Carvalho, E; Oliveira, P; Lopes, JM; Reis, RM Abstract: BACKGROUND: The epidermal growth factor receptor (EGFR) regulates important cellular processes and is frequently implicated in human tumors. Three EGFR polymorphisms have been described as having a transcriptional regulatory function: two single-nucleotide polymorphisms in the essential promoter region, -216G/T and -191C/A, and a polymorphic (CA)(n) microsatellite sequence in intron 1. We aimed to elucidate the roles of these EGFR polymorphisms in glioma susceptibility and prognosis. METHODS: We conducted a case-control study with 196 patients with glioma and 168 cancer-free controls. Unconditional multivariate logistic regression models were used to calculate ORs and 95% confidence intervals. A Cox regression model was used to evaluate associations with patient survival. False-positive report probabilities were also assessed. RESULTS: None of the EGFR -216G/T variants was significantly associated with glioma risk. The -191C/A genotype was associated with higher risk for glioma when the (CA)(n) alleles were classified as short for ≤16 or ≤17 repeats. Independently of the (CA)(n) repeat cutoff point used, shorter (CA)(n) repeat variants were significantly associated with increased risk for glioma, particularly glioblastoma and oligodendroglioma. In all tested models with different (CA)(n) cutoff points, only -191C/A genotype was consistently associated with improved survival of patients with glioblastoma. CONCLUSIONS: Our findings implicate EGFR -191C/A and the (CA)(n) repeat polymorphisms as risk factors for gliomas, and suggest -191C/A as a prognostic marker in glioblastoma. IMPACT: Our data support a role of these EGFR polymorphisms in determining glioma susceptibility, with potential relevance for molecularly based stratification of patients with glioblastoma for individualized therapies

2011-01-01T00:00:00Z Morais, N Mascarenhas, L Soares- Fernandes, JP Silva, A Magalhães, Z Moreira da Costa, A http://comum.rcaap.pt/handle/123456789/3557 2013-06-05T01:20:12Z 2013-01-01T00:00:00Z

Title: Primary spinal glioblastoma: A case report and review of the literature Authors: Morais, N; Mascarenhas, L; Soares- Fernandes, JP; Silva, A; Magalhães, Z; Moreira da Costa, A Abstract: Primary spinal glioblastoma (GBM) is a rare disease, with an aggressive course and a poor prognosis. We report a case of a 19-year-old male with a 4-week history of progressive weakness in both lower limbs, which progressed to paraparesis with a left predominance and difficulty in initiating urination over a week. Spine magnetic resonance imaging (MRI) showed an intramedullary expansile mass localised between T6 and T11. We performed a laminotomy and laminoplasty between T6 and T11 and the tumour was partially removed. Histopathological study was compatible with GBM. The patient was administered focal spine radiotherapy with chemotherapy with temozolamide. Serial MRI performed after the initial surgery demonstrated enlargement of the enhancing mass from T3 to T12 and subarachnoid metastatic deposits in C2 and C4, the pituitary stalk, interpeduncular cistern, left superior cerebellar peduncle and hydrocephalus. We review the literature with regard to the disease and treatment options, and report the unique features of this case. Primary spinal GBM is an extremely rare entity with a poor prognosis and a short survival time. An aggressive management of the different complications as they arise and improvement of current modes of treatment and new treatment options are required to improve survival and ensure better quality of life.

2013-01-01T00:00:00Z Costa, BM Ferreira, P Costa, S Canedo, P Oliveira, P Silva, AI Pardal, F Suriano, G Machado, JC Lopes, JM Reis, RM http://comum.rcaap.pt/handle/123456789/2817 2012-12-18T02:14:37Z 2007-01-01T00:00:00Z

Title: Association between functional EGF+61 polymorphism and glioma risk Authors: Costa, BM; Ferreira, P; Costa, S; Canedo, P; Oliveira, P; Silva, AI; Pardal, F; Suriano, G; Machado, JC; Lopes, JM; Reis, RM Abstract: PURPOSE: Epidermal growth factor (EGF) plays a critical role in cancer. A polymorphism in the EGF gene (EGF+61) may influence its expression and contribute to cancer predisposition and aggressiveness. In the present study, we aimed to elucidate the role of EGF+61 in glioma susceptibility and prognosis. EXPERIMENTAL DESIGN: A case-control study involving 197 glioma patients and 570 controls was done. Univariate and multivariate logistic regression analyses were used to calculate odds ratio (OR) and 95% confidence intervals (95% CI). False-positive report probability was also assessed. The luciferase reporter gene assay was used to ascertain the functional consequences of this polymorphism. RESULTS: Corroborating the univariate analysis, the multivariate model showed that the G allele conferred higher risks for gliomas (OR, 1.32; 95% CI, 1.04-1.67), glioblastomas (OR, 1.47; 95% CI, 1.02-2.10), and oligodendrogliomas (OR, 1.55; 95% CI, 1.07-2.23). The GG genotypes were associated with increased risk for gliomas (OR, 1.71; 95% CI, 1.07-2.73), glioblastomas (OR, 2.03; 95% CI, 1.02-4.05), and oligodendrogliomas (OR, 2.72; 95% CI, 1.18-6.28). In addition, the AG+GG genotypes were associated with higher risk for gliomas (OR, 1.52; 95% CI, 1.03-2.23) and oligodendrogliomas (OR, 2.80; 95% CI, 1.35-5.79). No significant association was observed between the EGF+61 polymorphism and glioblastoma or oligodendroglioma patients' overall survival. The luciferase reporter gene assay exhibited a significant increased promoter activity for the G variant compared with the reference A allele. CONCLUSIONS: These findings support the role of the EGF+61 polymorphism as a susceptibility factor for development of gliomas and show its implication on EGF promoter activity.

2007-01-01T00:00:00Z